No Data
No Data
Huiyu Pharmaceutical Gets Nod to Market Sodium Valproate Injection Concentrated Solution in Ireland
Sichuan Huiyu Pharmaceutical's (SHSE:688553) Shareholders May Want To Dig Deeper Than Statutory Profit
Huayu Pharmaceuticals (688553.SH): Plerixafor injection, Azacitidine for injection, and Setipiprant for injection have been granted market approval in Israel, Egypt, and Northern Ireland, respectively.
Gelonghui August 27th 丨 Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary Seacross Pharmaceuticals Ltd. recently received market approval for the company's products Pulisafu Injection, Azacitidine for Injection, and Cetuximab for Injection issued by the Israeli Ministry of Health, Egyptian Drug Authority, and the United Kingdom Medicines and Healthcare Products Regulatory Agency respectively.
Huiyu Pharmaceutical's Unit Gets Nod to Trial Tumor Drug
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
No Data